Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholder's Equity

v3.20.1
Consolidated Statements of Stockholder's Equity - USD ($)
$ in Thousands
Total
October 2018 Registered Direct Offering [Member]
June 2018 Public Offering [Member]
December 2019 Public Offering [Member]
June 2018 Financing Costs [Member]
LPC [Member]
Common stock [Member]
Common stock [Member]
Series A Convertible Preferred Stock [Member]
Common stock [Member]
Series B Convertible Preferred Stock [Member]
Common stock [Member]
October 2018 Registered Direct Offering [Member]
Common stock [Member]
June 2018 Public Offering [Member]
Common stock [Member]
December 2019 Public Offering [Member]
Common stock [Member]
LPC [Member]
Preferred Stock [Member]
Preferred Stock [Member]
Series A Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Preferred Stock [Member]
June 2018 Public Offering [Member]
Preferred Stock [Member]
December 2019 Public Offering [Member]
Additional paid-in capital [Member]
Additional paid-in capital [Member]
Series A Convertible Preferred Stock [Member]
Additional paid-in capital [Member]
Series B Convertible Preferred Stock [Member]
Additional paid-in capital [Member]
October 2018 Registered Direct Offering [Member]
Additional paid-in capital [Member]
June 2018 Public Offering [Member]
Additional paid-in capital [Member]
December 2019 Public Offering [Member]
Additional paid-in capital [Member]
June 2018 Financing Costs [Member]
Additional paid-in capital [Member]
LPC [Member]
Accumulated other comprehensive income (loss) [Member]
Accumulated deficit [Member]
Beginning Balance at Dec. 31, 2016 $ 610                                   $ 2,667               $ 5 $ (2,062)
Beginning Balance, Shares at Dec. 31, 2016             2,123                                          
Stock-based compensation expense 348                                   348                  
Settlement of stockholder loans with related parties 2,132                                   2,132                  
Settlement of stockholder loans with related parties, Shares             157                                          
Shares issued on subscription 64                                   64                  
Shares issued on subscription, Shares             5                                          
Shares held by OncoGenex Shareholders 3           $ 3                                          
Shares held by OncoGenex Shareholders, Shares             273,671                                          
Shares issued on conversion of Achieve common shares 13,048           $ 8                       13,040                  
Shares issued on conversion of Achieve common shares, Shares             821,012                                          
Shares cancelled on conversion of Achieve common shares             (2,285)                                          
Restricted Stock Unit Settlements, Shares             546                                          
Restricted Stock Unit Settlements withheld and retired to treasury (5)                                                     (5)
Restricted Stock Unit Settlements withheld and retired to treasury, Shares             (166)                                          
Shares issued           $ 2,306             $ 1                         $ 2,305    
Shares issued, Shares                         99,730                              
Purchase accounting adjustment (44)                                                     (44)
Net loss (10,583)                                                     (10,583)
Ending Balance at Dec. 31, 2017 7,879           $ 12                       20,556               5 (12,694)
Ending Balance, Shares at Dec. 31, 2017             1,194,793                                          
Stock-based compensation expense $ 854                                   854                  
Restricted Stock Unit Settlements, Shares 5,354           5,354                                          
Adjustment of fractional shares on reverse stock split, Shares             (38)                                          
Shares issued   $ 4,960 $ 12,194     1,279       $ 2 $ 1   $ 1                 $ 4,958 $ 12,193     1,278    
Shares issued, Shares                   1,789,258 1,160,500   96,000       9,158                      
Shares issued on exercise of warrants $ 1,324                                   1,324                  
Shares issued on exercise of warrants, Shares             330,500                                          
Shares issued on conversion of preferred shares               $ 2                       $ (2)                
Shares issued on conversion of preferred shares, Shares               2,144,750             (8,579)                          
Other comprehensive income (loss) (1)                                                   (1)  
Net loss (12,687)                                                     (12,687)
Ending Balance at Dec. 31, 2018 15,802           $ 18                       41,161               4 (25,381)
Ending Balance, Shares at Dec. 31, 2018             6,721,117             579                            
Stock-based compensation expense $ 1,201                                   1,201                  
Restricted Stock Unit Settlements, Shares 5,134           5,084                                          
Adjustments to final October 2018 financing costs $ 4       $ 116                           4           $ 116      
Cumulative adjustment on adoption of lease standard | ASU 2016-02 [Member] (3)                                                     (3)
Shares issued       $ 12,334   $ 792           $ 13                       $ 12,321   $ 792    
Shares issued, Shares                       12,577,504 374,000         6,256                    
Shares issued on exercise of warrants 4,199           $ 1                       4,198                  
Shares issued on exercise of warrants, Shares             1,107,813                                          
Shares issued on conversion of preferred shares                 $ 9                       $ (9)              
Shares issued on conversion of preferred shares, Shares               144,750 8,554,910           (579) (5,135)                        
Issuance of inducement warrants                                     3,925                 (3,925)
Net loss (16,395)                                                     (16,395)
Ending Balance at Dec. 31, 2019 $ 18,050           $ 41                       $ 63,709               $ 4 $ (45,704)
Ending Balance, Shares at Dec. 31, 2019             29,485,178             1,121